慢性乙型肝炎患者治疗前后血清sFas和sFasL的变化及其临床意义

目的　探讨各类慢性乙型肝炎(CHB)治疗前后血清可溶性Fas(sFas)和sFas配体(sFasL)的水平变 化及其意义。方法　用酶联免疫吸附试验(ELISA)检测118例各种类型CHB患者经前列腺素E1等药物治疗前 后血清sFas、sFasL的水平,并与30名健康献血者比较。结果　118例各种类型CHB患者的sFas明显高于正常 对照组(P<0.01、0.01、0.01、0.05),且重型肝炎(FH)>CHB重度>CHB中度>CHB轻度(P均<0.01),sFas 的升高与总胆红素(TBil)呈显著性正相关(r=0.605,P<0.01);FH和CHB重度的sFasL明显高于正常对照组 (P均<0.01)。恢复期各组sFas和sFasL均比治疗前明显降低(P均<0.01)。结论　血清sFas、sFasL的水平 与CHB病情密切相关,监测二者变化有助于判断病情和观察疗效。

The changes of serum soluble Fas and soluble Fas ligand levels in chronic hepatitis B and its clinical significance

Objective To investigate the changes and significance of serum soluble Fas (sFas) and soluble Fas ligand (sFasL) in patients with chronic hepatitis B(CHB) after prostaylandin E 1 (PGE 1) treatment. Methods Serum sFas and sFasL were detected by ELISA in 118 CHB patients before and after the treatment with PGE1, and 30 healthy persons served as normal controls. Results Serum sFas levels in 118 CHB patients were significantly higher than those in normal controls, serum sFas levels were correlated with disease activity, and related to the levels of total bilirubin (TBil) positively. Serum sFasL levels in hepatic failure patients and severe degree CHB patients were significantly higher than those in normal controls. After the treatment with PGE1, serum sFas and sFasL levels of all patients significantly decreased. Conclusions CHB patient has higher levels of serum sFas and sFasL; Serum sFas and sFasL are correlated with disease activity positively. Measurement of them may be helpful to diagnose pathological condition and evaluate therapeutic effect.